Exploring the Role of GLP-1 Agents in Managing Diabetic Foot Ulcers: A Narrative and Systematic Review

    September 2025 in “ Wound Repair and Regeneration ”
    Fiona Gruzmark, Gabriela E Beraja, Ivan Jozic, Hadar Lev‐Tov
    Image of study
    TLDR GLP-1 receptor agonists may help manage and prevent diabetic foot ulcers.
    The review examines the potential of GLP-1 receptor agonists (GLP-1RAs) in managing diabetic foot ulcers (DFUs), a common and costly complication of diabetes. GLP-1RAs, such as dulaglutide and semaglutide, may offer benefits by reducing plasma glucose, modulating wound repair, and improving microvascular function. The LEADER trial indicated that liraglutide reduced the risk of lower extremity amputations by 35%. However, side effects like nausea, vomiting, and gastrointestinal issues are noted. A systematic review of 19 RCTs with 1,345 participants found GLP-1RAs associated with greater lean body mass loss but did not increase DFU risk. Despite promising results, further research is needed to confirm their efficacy in DFU treatment.
    Discuss this study in the Community →